[go: up one dir, main page]

MX2014001271A - Tratamiento de diabetes de tipo 2 con fty720. - Google Patents

Tratamiento de diabetes de tipo 2 con fty720.

Info

Publication number
MX2014001271A
MX2014001271A MX2014001271A MX2014001271A MX2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A
Authority
MX
Mexico
Prior art keywords
fty720
diabetes
treatment
type
administering
Prior art date
Application number
MX2014001271A
Other languages
English (en)
Other versions
MX364643B (es
Inventor
Zhongmin Ma
Original Assignee
Zhongmin Ma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongmin Ma filed Critical Zhongmin Ma
Publication of MX2014001271A publication Critical patent/MX2014001271A/es
Publication of MX364643B publication Critical patent/MX364643B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos terapéuticos para la prevención y tratamiento de diabetes de tipo 2, que comprende administrar al paciente una cantidad efectiva de FTY720 o un análogo.
MX2014001271A 2011-08-03 2012-08-03 USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. MX364643B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161574441P 2011-08-03 2011-08-03
PCT/US2012/049565 WO2013020069A1 (en) 2011-08-03 2012-08-03 Treatment of type 2 diabetes with fty720

Publications (2)

Publication Number Publication Date
MX2014001271A true MX2014001271A (es) 2014-05-19
MX364643B MX364643B (es) 2019-05-03

Family

ID=46682917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001271A MX364643B (es) 2011-08-03 2012-08-03 USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.

Country Status (10)

Country Link
US (2) US8653026B2 (es)
EP (1) EP2739277B1 (es)
JP (1) JP2014521697A (es)
CN (1) CN103930101A (es)
AU (1) AU2012289921B2 (es)
CA (1) CA2843224C (es)
DK (1) DK2739277T3 (es)
HK (1) HK1198467A1 (es)
MX (1) MX364643B (es)
WO (1) WO2013020069A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
DE60017115T2 (de) 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
JP3790686B2 (ja) * 2001-08-03 2006-06-28 独立行政法人理化学研究所 血糖降下剤
AU2003243501A1 (en) * 2002-06-07 2003-12-22 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
CA2501677A1 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes
WO2009061374A2 (en) * 2007-11-02 2009-05-14 Concert Pharmaceuticals, Inc. Deuterated fingolimod

Also Published As

Publication number Publication date
AU2012289921A1 (en) 2014-02-06
US20140107024A1 (en) 2014-04-17
EP2739277B1 (en) 2016-11-23
DK2739277T3 (en) 2017-02-27
AU2012289921B2 (en) 2017-05-04
US20130123172A1 (en) 2013-05-16
WO2013020069A1 (en) 2013-02-07
JP2014521697A (ja) 2014-08-28
CA2843224A1 (en) 2013-02-07
CA2843224C (en) 2020-04-21
MX364643B (es) 2019-05-03
EP2739277A1 (en) 2014-06-11
HK1198467A1 (en) 2015-05-08
CN103930101A (zh) 2014-07-16
US8653026B2 (en) 2014-02-18
NZ620025A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
IN2014KN02830A (es)
MX2015008114A (es) Derivados de exendina-4.
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
IN2012DN00624A (es)
EA201201657A1 (ru) Лечение диабета
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
WO2012015758A3 (en) Methods of treating pain
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2012000006A (es) L-serina para usarse como un farmaco para prevenir y/o tratar una respuesta inflamatoria de la piel.
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
EP3449917A3 (en) Tapentadol for preventing chronification of pain
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
UA115079C2 (uk) Сполуки як інгібітори діацилгліцеринацилтрансферази

Legal Events

Date Code Title Description
FG Grant or registration